Vienna-based Biotech raises €10M to fight Metabolic diseases and Parkinson’s

29/06/2016 - 2 minutes

AFFiRiS has received €10M from previous investors and one additional backer, adding up to €130M in total funding (half from grants and licensing incomes). This money fuels a pipeline in cardiometabolic and neurodegenerative diseases as more candidates break into clinical development.

affiris_peptide_vaccines_cholesterol_parkinsonsBased at the Campus Vienna Biocenter (Austria), AFFiRiS is developing immunotherapies to prevent chronic diseases. Some of its targets are high cholesterol, diabetes, Alzheimer’s and Parkinson’s.

Its vaccines are short synthetic peptides created with Affitome, AFFiRiS’ proprietary platform. These short peptides function as B-cell epitopes, mimicking the part of a protein that antibodies would recognize as a threat. As a result, they can create an immune response against proteins related to diseases (also a popular strategy in allergy, for example).

This new €10M round from AFFiRiS follows another €10M round made in June 2015. One of its existing backers are the Strüngmann brothers (via Santo Holding), who are famous for having sold the generic Pharma Hexal to Novartis for $7.5Bn in 2005.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following:


Support Us

Become a Member